medigraphic.com
ISSN 1405-1699 (Impreso)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2011, Número 2

<< Anterior Siguiente >>

Alerg Asma Inmunol Pediatr 2011; 20 (2)


Calidad de vida en inmunodeficiencias primarias

Vargas PA, Bustamante OJC, Muriel VR, Espinosa RF

Idioma: Español
Referencias bibliográficas: 41
Paginas: 57-64
Archivo PDF: 72.03 Kb.


RESUMEN

Las inmunodeficiencias primarias son enfermedades genéticas que se caracterizan por una predisposición a desarrollar infecciones repetidas, graves, por gérmenes oportunistas y que pueden poner en peligro la vida cuando no se diagnostican y tratan oportunamente. El retraso en el diagnóstico se asocia con frecuencia a daño permanente en órganos vitales y discapacidad que por lo general es proporcional al retraso en el diagnóstico y el inicio de tratamiento. Gracias a los avances en el diagnóstico y tratamiento de estas enfermedades, cada día se tienen más pacientes que sobreviven y llegan a la edad adulta. En los últimos años han surgido diversos instrumentos que permiten evaluar la calidad de vida de pacientes en edad pediátrica que sufren de enfermedades crónicas. En este artículo hacemos una revisión de los instrumentos disponibles para evaluar la calidad de vida en pediatría y de los reportes que existen sobre su uso para evaluarla en pacientes que sufren de inmunodeficiencias primarias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dinakar C. Alleviating disease burden in primary immunodeficiency diseases. Ann Allergy Asthma Immunol 2006; 96-2: 260-262.

  2. Towson MD. Treatment experiences with preferences of patients with primary immune deficiency diseases: first national survey. Immune Deficiency Foundation 2003.

  3. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125: S182-94.

  4. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007; 27: 497–502.

  5. Leiva LE, Zelazco M, Oleastro M et al, for the Latin American Group for Primary Immunodeficiency Diseases. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol 2007; 27: 101–8.

  6. Notarangelo LD, Fischer A, Geha RS et al. Primary immunodeficiencies: 2009 update. International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2009; 124: 1161-78.

  7. National Institutes of Health. Primary immunodeficiency. Bethesda, MD: US dept of Health and Human Services. National Institute of Child Health and Human development 1999; 99-4149.

  8. Malphettes M, Laurence G, Carmagnat M et al. Late-onset combined immune deficiency: A subset of common variable immunodeficiency with severe T cell defect. Clinical Infectious Diseases 2009; 49: 1329–38.

  9. Nowak-Wegrzyn A, Lederman HM. Supply, use, and abuse of intravenous immunoglobulin. Curr Opin Pediatr 1999; 11(6): 533–9.

  10. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42(7): 839-48.

  11. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am 2008; 28: 413-37.

  12. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117(4): 525-53.

  13. Pane S, Solans M, Gaite L et al. Instrumentos de calidad de vida relacionada con la salud en la edad pediátrica. Revisión sistemática de la literatura: actualización. Agència d’Avaluació de Tecnologia i Recerca Mèdiques. Barcelona, 2006.

  14. Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child 2001; 84: 205-11.

  15. Clarke SA, Eiser C. The measurement of health-related quality of life (QOL) in pediatric clinical trials: a systematic review. Health and Quality of Life Outcomes 2004; 2: 66.

  16. Varni JW, Burwinkle TM, Lane MM. Health-related quality of life measurement in pediatric clinical practice: An appraisal and precept for future research and application. Health and Quality of Life Outcomes 2005; 3: 34.

  17. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research 2002; 11: 193–205.

  18. Eiser C, Jenney M. Measuring quality of life. Arch Dis Child 2007; 92: 348–350.

  19. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6(6): 434-442.

  20. Winkelstein JA, Conley ME, James C et al. Adults with X-linked agammaglobulinemia: Impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore) 2008; 87(5): 253-258.

  21. Sigstad HM, Stray-Pedersen A, Froland SS. Coping, quality of life and hope in adults with primary antibody deficiencies. Health Qual Life Outcomes 2005; 3: 31.

  22. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26(1): 65-72.

  23. Howard V, Greene JM, Pahwa S et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006; 118(2-3): 201-208.

  24. Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2004; 93(2): 160-165.

  25. Greenwell CA, Mehta R, Hester JD et al. Efficacy of IGIV in patients with IgG subclass deficiency and/or antibody deficiency in a one year open label study of quality of life, innate immunity, and correction of subclass/antibody levels. J Allergy Clin Immunol 2007; 119 S1: S251.

  26. Kanani AS, Schellenberg RR, Stark DF. A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary immunodeficiency receiving IVIG. J Allergy Clin Immunol 2007; 119 S1: S251.

  27. Nguyen D, Catanzaro J, Apte S et al. Quality of life is maintained in common variable immunodeficiency during longterm immunoglobulin replacement therapy. J Allergy Clin Immunol 2010; 125 S1: AB141.

  28. Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005; 14(7): 1683-91.

  29. Gardulf A, Borte M, Ochs HD, Nicolay U; Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126(1): 81-8.

  30. Gardulf A, Nicolay U, Asensio O et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG Self-infusions at Home. J Allergy Clin Immunol 2004; 114(4): 936-942.

  31. Borte M, Ritchie B, Plebani A et al. Improvement in quality of life measurements in newly diagnosed patients with primary immunodeficiency receiving directly initiated subcutaneous replacement therapy with vivaglobin: 551. J Allergy Clin Immunol 2010; 125(2) S1: AB140.

  32. Berger M, Murphy E, Riley P et al. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Southern Medical J August 2010 (Published ahead of print).

  33. Mozaffari H, Pouprak Z, Pourseyed S et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol 2006; 5(1): 23-7.

  34. Zebracki K, Palermo TM, Hostoffer R, Duff K, Drotar D. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol 2004; 93: 557–561.

  35. Fasth A, Nyström J. Quality of life and health care resources utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28(4): 370-378.

  36. Soresina A, Nacinovich R, Bomba M et al. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol 2009; 29: 501–7.

  37. Shearer WT, Notarangelo LD, Griffith LM. Treatment of immunodeficiency: Long-term outcome and quality of life. J Allergy Clin Immunol 2008; 122(6): 1065-1068.

  38. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability and validity. Amb Paediatr 2003; 3: 329–341.

  39. Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 1999; 37(2): 126-39.

  40. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39(8): 800-12.

  41. Boyle J, James C, Lederman HM. The socioeconomic status of adults with X-linked agammaglobulinemia. J Allergy Clin Immunol 2005; 115 S1: S158.




2020     |     www.medigraphic.com